ZNTL - Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday? | Benzinga
Tuesday, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) announced that the FDA has placed a partial clinical hold on the following studies of azenosertib:
- Phase 1 ZN-c3-001 dose-escalation study in solid tumors.
- Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC).
- Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).
This action follows two recent deaths due to presumed sepsis in the DENALI study.
“Over 500 patients have been treated with azenosertib monotherapy to date, and ...